Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03720353 · ClinicalTrials.gov registry record · Phase 1

Pharmacological Intervention for Symptomatic Snoring

A Phase 1 study, sponsored by Brigham and Women's Hospital.

Completed
Registry status
Phase 1
Development phase
27
Enrollment target

NCT03720353 is a Phase 1 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 27 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03720353, a Phase 1 study, has completed, sponsored by Brigham and Women's Hospital.

COMPLETED
Registry status
Phase 1
Development phase
27 participants
Enrollment target

Study Summary

Currently, there is no pharmacological intervention capable of maintaining airway patency for the treatment of snoring and airflow limitation during sleep. Here we study the effect of pharmacological stimulation of the pharyngeal muscles on snoring severity, in a randomized quadruple-blind, crossover study.

Interventions

  • DRUG Placebo
  • DRUG SAS2094AH and SAS2094BH
  • DRUG SAS2094AL and SAS2094BL

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2018-12-17
Est. Completion 2019-12-10
Phase Phase 1

Sponsor

Brigham and Women's Hospital

937 total trials

What the Registry Record Tells You About NCT03720353

The ClinicalTrials.gov registry entry for NCT03720353 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT03720353 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03720353 about?

NCT03720353 is a clinical study titled "Pharmacological Intervention for Symptomatic Snoring". Currently, there is no pharmacological intervention capable of maintaining airway patency for the treatment of snoring and airflow limitation during sleep. Here we study the effect of pharmacological stimulation of the pharyngeal muscles on snoring severity, in a randomized quadruple-blind, crossove...

What is the current status of trial NCT03720353?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2018-12-17. Estimated completion is 2019-12-10.

What interventions are being tested in trial NCT03720353?

The interventions under investigation include: Placebo (DRUG), SAS2094AH and SAS2094BH (DRUG), SAS2094AL and SAS2094BL (DRUG).

Who is sponsoring clinical trial NCT03720353?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.